144 ·Filed May 15, 2026

ANAB

ANAPTYSBIO, INC
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001950047-26-004587
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale following option exercise, typical for officer compensation. The small size relative to market cap (~$1.8B) suggests no material signal. Monitor for any cluster of insider sales or Form 4 filings in coming weeks, but no immediate action warranted.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ANAB ▼ -3.00% at T+60d
NEUTRAL call ✗ call lost -3.00% · α vs SPY -7.85% · entry $58.74 → $56.98
Entry anchored
May 15, 03:59 PM ET
via exchange tick
T+1d
+1.75%
call +1.75% · α +2.40%
$59.77
settled 5mo ago
T+5d
-1.65%
call -1.65% · α -3.27%
$57.77
settled 4mo ago
T+20d
-1.92%
call -1.92% · α -3.50%
$57.61
settled 4mo ago
T+60d
-3.00%
call -3.00% · α -7.85%
$56.98
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 15, 2026, indicating intent to sell 10,000 shares of common stock with an approximate market value of $632,543. The shares were acquired via stock option exercise on the same day. This is a routine insider sale following option exercise, not a material signal of deteriorating fundamentals.

Key Facts

  • Insider Dennis Mulroy (Officer) filed Form 144 to sell 10,000 shares
  • Estimated sale value: ~$632,543 based on filing date market price
  • Shares acquired via stock option exercise on May 15, 2026
  • Sale represents a modest portion of total holdings (relative to 29,100,902 shares outstanding)
  • No other insider sales or unusual trading patterns noted in last 30 days

Financial Impact

Sale of 10,000 shares valued at ~$632,543, representing ~0.03% of shares outstanding

dilution

Risk Factors

  • Insider may not execute the sale (Form 144 is intent, not obligation)
  • If followed by additional insider sales, could indicate broader insider sentiment shift

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-004587
Document: 0001950047-26-004587-index.html0001950047-26-004587
Document: 0001950047-26-004587.txt0001950047-26-004587
24 reports for ANAB
Performance horizon
67% Hit rate 12 of 18 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$56.02 $53.87▼ −3.84%▼ −2.09%$48.53 (−13.37%)
Jun 29, 2026
13w ago
144
BEARISH ★ 6/10
$67.50 $53.61▲ +20.58%▲ +19.55%$48.53 (+28.10%)
Jun 29, 2026
13w ago
DEFA14A
NEUTRAL ★ 2/10
$67.50 $53.61▼ −20.58%▼ −19.55%$48.53 (−28.10%)
Jun 26, 2026
13w ago
144
BEARISH ★ 6/10
$65.97 $54.15▲ +17.92%▲ +17.64%$48.53 (+26.44%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$59.43 $50.29▼ −15.38%▼ −16.54%$48.53 (−18.34%)
Jun 17, 2026
15w ago
144
BEARISH ★ 5/10
$57.51 $54.15▲ +5.84%▲ +6.38%$48.53 (+15.61%)
Jun 15, 2026
15w ago
144
BEARISH ★ 6/10
$57.61 $62.51▼ −8.51%▼ −8.31%$48.53 (+15.76%)
Jun 11, 2026
16w ago
144
BEARISH ★ 6/10
$56.07 $66.39▼ −18.41%▼ −16.63%$48.53 (+13.45%)
Jun 10, 2026
16w ago
144
BEARISH ★ 5/10
$54.24 $66.59▼ −22.77%▼ −20.88%$48.53 (+10.53%)
Jun 8, 2026
16w ago
144
BEARISH ★ 5/10
$51.63 $67.33▼ −30.40%▼ −28.95%$48.53 (+6.00%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access